Stocks / Stock overview

Hinge Health, Inc. (HNGE)

$87.35-5.92%Aft $86.00 (-1.55%)Market cap $7.05B

NYSE · Price as of · Delayed Quote

Stock Scorer
Scoring…
Analyst consensus
Buy$106.47
  • Analysts15
  • Implied upside+21.9%
  • Target range$85.00 to $140.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 3, 2026in 66 days
  • EPS expected$0.61 +40%
  • A year ago$0.44
  • Revenue expected$224.7M +46%
  • Estimate range$0.57 to $0.78
Consensus of 12 analysts for the quarter ending September 30, 2026. Beat the estimate in 3 of the last four quarters. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
144August 28, 2026View on EDGAR
4August 27, 20264
144August 25, 2026View on EDGAR
144August 25, 2026View on EDGAR
4August 24, 2026View on EDGAR
4August 24, 2026View on EDGAR
4August 21, 2026View on EDGAR
4August 21, 20264
All SEC filings

Frequently asked questions

When does HNGE report earnings?

Hinge Health, Inc. (HNGE) is scheduled to report quarterly results on November 3, 2026. The 12-analyst consensus is $0.61 per share on revenue of $224.7M for the quarter ending September 30, 2026, against $0.44 and $154.2M a year earlier. It has beaten the consensus EPS estimate in 3 of the last four quarters.

What do analysts expect for HNGE?

15 analysts cover Hinge Health, Inc. (HNGE). The consensus rating is Buy. The average price target is $106.47, in a range of $85.00 to $140.00.

Are insiders buying or selling HNGE?

We have no qualifying Form 4 insider purchases or sales on record for Hinge Health, Inc. (HNGE). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see HNGE SEC filings?

Recent filings are listed on this page, newest first. The latest is a 144 filed August 28, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.